Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Mon, 27.09.2021       Formycon AG

  Press Release // September 27, 2021 Formycon Reports on Virtual Annual General Meeting 2021 - Shareholders approve all items on the agenda - Management Board reports in detail on ongoing development projects - Supervisory Board and Management Board ratified by a large majority Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) held its  [ … ]
Thu, 23.09.2021       Formycon

First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN: DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes stuft die Aktie auf BUY herauf und bestätigt sein Kursziel von EUR 78,00. Zusammenfassung: Die Umsatzerlöse in H1/21 in Höhe von €20,3 Mio. (FBe €21,0 Mio.; H1/20: €16,5 Mio.) lagen nah [ … ]
Tue, 21.09.2021       Formycon AG

  Press Release // September 21, 2021 Formycon Publishes Half-Year Results for 2021 - Group turnover above H1 half-year level at Euro 20.3 million - EBITDA of Euro -9.7 million and half-year results of Euro -10.2 million in line with plans - Result due to investments in the non-partnered projects FYB206 and FYB207 - Significant progress in th [ … ]
Wed, 15.09.2021       Formycon AG

Press Release // September 15, 2021 Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021 Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug developme [ … ]
Wed, 11.08.2021       Formycon AG

  Press Release // August 11, 2021 Formycon reports on the status of FYB207 development - Efficient neutralization of SARS-CoV-2 variants-of-concern - Production for preclinical and clinical product established at fast track - Expansion of preclinical efficacy testing planned - Phase I/IIa clinical trial expected to start first half of 2022  [ … ]
Thu, 05.08.2021       Formycon AG

Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // August 5, 2021 Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA) Munich - Formyco [ … ]
Mon, 12.07.2021       Formycon AG

Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // July 12, 2021 Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A [ … ]
Mon, 05.07.2021       Formycon

First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN: DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes stuft die Aktie auf ADD herab und bestätigt sein Kursziel von EUR 78,00. Zusammenfassung: Im vergangenen November gab Formycon bekannt, dass sie die BLA (Biologics License Application) für ihr Lucentis-Bio [ … ]
Wed, 30.06.2021       Formycon AG

  Press Release // June 30, 2021 Formycon Reports Financial Results for the First Quarter of 2021 - Sales and other earnings total EUR 9.4 million - EBITDA is EUR -1.7 million - EBIT and net result in line with expectations at around EUR -2.0 million each Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today presented the sales and ea [ … ]
Tue, 29.06.2021       Formycon AG

Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // June 29, 2021 Formycon and Bioeq announce submission of the marketing authorization application for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the European Medicines Agency (EMA) Munich - Formycon AG (ISI [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Monday, 09.09.2024, Calendar Week 37, 253rd day of the year, 113 days remaining until EoY.